Opendata, web and dolomites

VOGAS SIGNED

Screening of Gastric Cancer via Breath volatile organic compounds by Hybrid Sensing Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VOGAS project word cloud

Explore the words cloud of the VOGAS project. It provides you a very rough idea of what is the project "VOGAS" about.

organic    prototypes    metal    detecting    origin    countries    optimized    spectrometry    cancer    chromatography    nanoparticles    america    panels    compounds    international    obtaining    dimensional    data    bacterial    breath    dysplasia    invasive    brazil    latvia    expertise    gold    combine    intestinal    stage    members    techniques    portable    lines    acquired    chances    cured    building    exhaled    lack    vocs    concentration    atrophy    human    headspace    analyser    gastric    components    good    device    burden    lesions    composition    individuals    volatile    patients    tool    competences    voc    mechanisms    eastern    american    parallel    utilizing    spectroscopic    validated    screening    clinical    electronic    sensors    gas    cell    confounding    coupled    tissue    vital    gc    infrared    disease    colombia    orthogonal    infection    analytical    ms    flora    first    mid    latin    mass    collaborations    precancerous    ukraine    compact    geographical    chile    nose    enrolled    schemes    oxide    pylori    metaplasia    diagnosed    previously   

Project "VOGAS" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙781˙179 €
 EC max contribution 3˙781˙179 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 650˙363.00
2    LATVIJAS UNIVERSITATE LV (RIGA) participant 510˙000.00
3    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) participant 395˙535.00
4    UNIVERSITAET ULM DE (ULM) participant 385˙000.00
5    JLM INNOVATION GMBH DE (TUEBINGEN) participant 375˙000.00
6    Teknologian tutkimuskeskus VTT Oy FI (Espoo) participant 358˙875.00
7    UPPSALA UNIVERSITET SE (UPPSALA) participant 253˙727.00
8    UNIVERSIDAD DE PAMPLONA CO (PAMPLONA) participant 250˙625.00
9    NATIONAL CANCER INSTITUTE UA (KIYV) participant 210˙000.00
10    HOSPITAL UNIVERSITARIO SAN IGNACIO CO (BOGOTA) participant 209˙984.00
11    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 182˙068.00
12    FUNDACAO ANTONIO PRUDENTE BR (SAO PAULO) participant 0.00

Map

 Project objective

Gastric cancer has good chances to be cured if diagnosed at an early stage; currently, there is lack of a reliable non-invasive screening tool. Eastern Europe and Latin America are among the geographical areas with high burden of the disease.

This project is aiming at developing a non-invasive gastric cancer screening tool by detecting characteristic panels of volatile organic compounds (VOCs). The mechanisms of VOC origin and their composition in gastric cancer patients will be addressed via headspace analysis of cancer tissue, cell-lines, and bacterial flora; VOCs identified during this analysis will be compared to the compounds present in human breath, both via gas chromatography coupled to mass spectrometry (GC-MS).

Based on this data, a new type of breath analyser will be developed and validated building upon previously acquired expertise of the consortium members. Specifically, the exhaled breath analyser will combine electronic nose concepts utilizing gold nanoparticles and metal oxide sensors with orthogonal mid-infrared spectroscopic techniques for obtaining multi-dimensional analytical data sets; furthermore, compact pre-concentration schemes will be evaluated. All components will be integrated into several prototypes of portable and optimized devices.

The clinical studies will be conducted in parallel in European (Latvia, Ukraine) and Latin American (Colombia, Brazil, Chile) countries with high disease burden. Patients with gastric cancer and individuals with and without precancerous lesions (dysplasia, atrophy, intestinal metaplasia) will be enrolled. The role of confounding factors including H.pylori infection will be addressed.

As the main result, we expect to provide the first reliable non-invasive gastric cancer screening device based on exhaled breath analysis concepts for future large-scale implementation. The development of according research competences and international collaborations therefore is the most vital component of this project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VOGAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VOGAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More